```
     FILE 'REGISTRY' ENTERED AT 15:36:27 ON 22 OCT 2009
                  EXP HEPARIN/CN
L1             1 S E3
                  EXP LEUCINE/CN
L2             2 S E3
L3             1 S N-ACETYLCYSTEINE/CN
L4            12 S ISOLEUCINE/CN OR CYSTEINE/CN OR PHENYLALANINE/CN OR LYSINE/CN

     FILE 'HCAPLUS' ENTERED AT 15:37:48 ON 22 OCT 2009
L5         30466 S L1
L6        174610 S L2-L4
L7           703 S L5 AND L6
L8        161250 S PULMONARY OR INHALER OR INHALABLE OR INHALED OR INHALATION
L9            92 S L7 AND L8
L10           26 S L9 AND (PY<2004 OR AY<2004 OR PRY<2004)
```

```
=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 15:36:27 ON 22 OCT 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 OCT 2009  HIGHEST RN 1189417-78-4
DICTIONARY FILE UPDATES:  21 OCT 2009  HIGHEST RN 1189417-78-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> exp heparin/cn
E1            1     HEPAREMIN/CN
E2            1     HEPAREXINE/CN
E3            1 --> HEPARIN/CN
E4            1     HEPARIN (PHYSARUM POLYCEPHALUM STRAIN LU-353)/CN
E5            1     HEPARIN 3-PYRIDYLMETHYL ESTER/CN
E6            1     HEPARIN 4-HYDROXY-N,N-DIMETHYLBUTYRAMIDE/CN
E7            1     HEPARIN ACETATE/CN
E8            1     HEPARIN ACETYLGLUCOSAMINE DEACETYLASE/CN
E9            1     HEPARIN AFFIN REGULATORY PEPTIDE/CN
E10           1     HEPARIN BENZETHONIUM SALT/CN
E11           1     HEPARIN BENZYL ESTER/CN
E12           1     HEPARIN BENZYL ESTER SODIUM SALT/CN

=> s e3
L1            1 HEPARIN/CN

=> exp leucine/cn
E1            1     LEUCINANILIDE/CN
E2            1     LEUCINANILIDE, N-PHOSPHONO-L-ALANYL-, BIS(P-NITROBENZYL) EST
                    ER, L-/CN
E3            2 --> LEUCINE/CN
E4            1     LEUCINE B-NAPHTHYLAMIDASE/CN
E5            1     LEUCINE 2,2,2-TRICHLOROETHYL ESTER/CN
E6            1     LEUCINE 2,3-AMINOMUTASE/CN
E7            1     LEUCINE 2-BROMOETHYL ESTER HYDROCHLORIDE/CN
E8            1     LEUCINE 2-NAPHTHYLAMIDASE/CN
E9            1     LEUCINE 2-NAPHTHYLAMIDE/CN
E10           1     LEUCINE 2-OCTYLDODECYL ESTER/CN
E11           1     LEUCINE 2-OXOGLUTARATE TRANSAMINASE/CN
E12           1     LEUCINE 3-PHENYL-2-THIOHYDANTOIN/CN
```

```
=> s e3
L2            2 LEUCINE/CN

=> s N-acetylcysteine/cn
L3            1 N-ACETYLCYSTEINE/CN

=> s isoleucine/cn or cysteine/cn or phenylalanine/cn or lysine/cn or valine/cn or
methionine/cn
              2 ISOLEUCINE/CN
              2 CYSTEINE/CN
              2 PHENYLALANINE/CN
              2 LYSINE/CN
              2 VALINE/CN
              2 METHIONINE/CN
L4           12 ISOLEUCINE/CN OR CYSTEINE/CN OR PHENYLALANINE/CN OR LYSINE/CN
                OR VALINE/CN OR METHIONINE/CN

=> file hcaplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                  49.11      49.33

FILE 'HCAPLUS' ENTERED AT 15:37:48 ON 22 OCT 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 22 Oct 2009  VOL 151 ISS 17
FILE LAST UPDATED: 21 Oct 2009  (20091021/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Aug 2009

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l1
L5         30466 L1

=> s l2-l4
           43849 L2
            8636 L3
          158080 L4
```

```
L6      174610 (L2 OR L3 OR L4)

=> s l5 and l6
L7         703 L5 AND L6

=> s pulmonary or inhaler or inhalable or inhaled or inhalation
         113710 PULMONARY
           2774 INHALER
           1389 INHALABLE
          18055 INHALED
          44626 INHALATION
L8      161250 PULMONARY OR INHALER OR INHALABLE OR INHALED OR INHALATION

=> s l7 and l8
L9           92 L7 AND L8

=> s l9 and (PY<2004 or AY<2004 or PRY<2004)
       24038746 PY<2004
        4808272 AY<2004
        4281581 PRY<2004
L10          26 L9 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> d l10 1-26 ti abs bib

L10  ANSWER 1 OF 26  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Pharmaceutical compositions and method for treatment of chronic
     inflammatory diseases
AB   This invention defines novel compns. that can be used for clin. treatment
     of a class of chronic inflammatory diseases.  Increased generation of
     carbonyl substances, namely aldehydes and ketones, occurs at sites of
     chronic inflammation and is common to the etiologies of all of the clin.
     disorders addressed herein.  Such carbonyl substances are cytotoxic and
     addnl. serve to perpetuate and disseminate the inflammatory process.  This
     invention defines use of compns., the orally administered required primary
     agents of which are primary amine derivs. of benzoic acid capable of
     covalently reacting with the carbonyl substances.  P-Aminobenzoic acid is
     an example of the required primary agent of the present invention.  PABA
     has a small mol. weight, is water-soluble, has a primary amine group which
     reacts with carbonyl-containing substances and is tolerated by the body in
     relatively high dosages for extended periods.  The method includes
     administration of a composition comprising: (1) an orally consumed
     therapeutically effective amount of at least one required primary agent; (2)
     at least one required previously known medicament co-agent recognized as
     effective to treat a chronic inflammatory disease addressed herein
     administered to the mammalian subject via the oral route; and (3) one or
     more addnl. orally consumed required co-agent selected from the group
     consisting of antioxidants, vitamins, metabolites at risk of depletion,
     sulfhydryl co-agents, co-agents which may facilitate glutathione activity
     and nonabsorbable primary amine polymeric co-agents; so as to-produce an
     additive or synergistic physiol. effect of an anti-inflammatory nature.
AN   2008:1156137  HCAPLUS <<LOGINID::20091022>>
DN   149:409732
TI   Pharmaceutical compositions and method for treatment of chronic
     inflammatory diseases
IN   Shapiro, Howard K.
PA   USA
SO   U.S. Pat. Appl. Publ., 35pp., Cont.-in-part of U.S. Ser. No. 924,945.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 5
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20080234380	A1	20080925	US 2008-70518	20080220 <--
	US 20050090553	A1	20050428	US 2004-924945	20040824 <--
PRAI	US 1992-906909	B2	19920630 <--		
	US 1994-241603	B2	19940511 <--		
	US 1997-814291	B2	19970310 <--		
	US 2000-610073	B2	20000705 <--		
	US 2004-924945	A2	20040824		

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L10 ANSWER 2 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response

AB The invention provides novel active agents (e.g. peptides, small organic mols., amino acid pairs, etc.) that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiments, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route. Peptide preparation is included.

AN 2007:151052 HCAPLUS <<LOGINID::20091022>>

DN 146:244343

TI Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response

IN Fogelman, Alan M.; Navab, Mohamad

PA The Regents of the University of California, USA

SO U.S. Pat. Appl. Publ., 313pp., Cont.-in-part of U.S. Ser. No. 423,830.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070032430	A1	20070208	US 2006-407390	20060418 <--
	US 6664230	B1	20031216	US 2000-645454	20000824 <--
	US 20030045460	A1	20030306	US 2001-896841	20010629 <--
	US 6933279	B2	20050823		
	CN 1375299	A	20021023	CN 2001-103876	20010823 <--
	CN 1739787	A	20060301	CN 2005-10103876	20010823 <--
	CN 1911439	A	20070214	CN 2006-10100670	20010823 <--
	CN 1931358	A	20070321	CN 2006-10100667	20010823 <--
	CN 1931359	A	20070321	CN 2006-10100669	20010823 <--
	CN 1943781	A	20070411	CN 2006-10100668	20010823 <--
	EP 1864675	A1	20071212	EP 2007-7775	20010823 <--
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
	US 20030171277	A1	20030911	US 2002-187215	20020628 <--
	US 7144862	B2	20061205		
	US 20030229015	A1	20031211	US 2002-273386	20021016 <--
	US 7166578	B2	20070123		
	US 20040266671	A1	20041230	US 2003-423830	20030425 <--
	US 7199102	B2	20070403		
	JP 2006056899	A	20060302	JP 2005-304531	20051019 <--
	JP 4205713	B2	20090107		
	JP 2006312650	A	20061116	JP 2006-220831	20060814 <--
	JP 2007277250	A	20071025	JP 2007-118451	20070427 <--
	US 20080095821	A1	20080424	US 2007-830497	20070730 <--
	JP 2008150358	A	20080703	JP 2007-250264	20070926 <--
	AU 2007237157	A1	20071213	AU 2007-237157	20071126
	AU 2007237157	B2	20090409		
	ZA 2007010184	A	20081126	ZA 2007-10184	20071126

```
     US 20080293639       A1    20081127    US 2007-950315         20071204
     AU 2009202705        A1    20090723    AU 2009-202705         20090703 <--
PRAI US 2000-645454       A2    20000824  <--
     US 2001-896841       A2    20010629  <--
     US 2002-187215       A2    20020628  <--
     US 2002-273386       A2    20021016  <--
     US 2003-423830       A2    20030425  <--
     US 2005-676431P      P     20050429
     US 2005-697495P      P     20050707
     CN 2001-103876       A3    20010823  <--
     CN 2001-817280       A3    20010823  <--
     CN 2005-10103876     A3    20010823  <--
     EP 2001-966198       A3    20010823  <--
     JP 2002-520844       A3    20010823  <--
     WO 2001-US26497      A2    20010823  <--
     JP 2005-304531       A3    20051019
     AU 2006-200035       A3    20060106
     US 2006-407390       A1    20060418
     JP 2006-220831       A3    20060814
     AU 2007-237157       A3    20071126
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS   MARPAT 146:244343
OSC.G   1     THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L10  ANSWER 3 OF 26  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Methods of cardioprotection using dichloroacetate in combination with an
     inotrope
AB   The invention provides methods for maintaining or improving cardiac
     function after a cardiac function disturbing event by the use of
     cardioprotective dichloroacetate (DCA) and a inotropic drug.  The
     invention also provides pharmaceutical compns. comprising the combination
     of DCA and inotropic drug, pharmaceutically acceptable carriers and
     optional other therapeutic agents.  Also provided are the dosage protocols
     for the DCA and inotropic drug combination.
AN   2006:891335  HCAPLUS <<LOGINID::20091022>>
DN   145:263302
TI   Methods of cardioprotection using dichloroacetate in combination with an
     inotrope
IN   Lopaschuk, Gary D.; Collins-Nakai, Ruth
PA   University of Alberta, Can.
SO   U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S. Ser. No. 13,666.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 5
     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     ---------------      ----   --------    --------------------   --------
PI   US 20060194878        A1    20060831    US 2005-229101         20050916 <--
     US 6693133            B1    20040217    US 2002-268069         20021007 <--
     US 20040162346        A1    20040819    US 2004-778791         20040213 <--
     US 7432247            B2    20081007
     US 20050282896        A1    20051222    US 2004-13666          20041215 <--
     WO 2006063446         A1    20060622    WO 2005-CA1894         20051215
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
             MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
             SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
             VN, YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
```

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

WO 2007030944 A2 20070322 WO 2006-CA1523 20060915
WO 2007030944 A3 20070503
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRAI US 2002-268069 A1 20021007 <--
US 2004-778791 A2 20040213
US 2004-13666 A2 20041215
US 2005-229101 A 20050916
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

L10 ANSWER 4 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Methods of cardioprotection using dichloroacetate in combination with an inotrope
AB The invention provides methods for maintaining or improving cardiac function after a cardiac function disturbing event by the use of cardioprotective dichloroacetate (DCA) and a inotropic drug. The invention also provides pharmaceutical compns. comprising the combination of DCA and inotropic drug, pharmaceutically acceptable carriers and optional other therapeutic agents. Also provided are the dosage protocols for the DCA and inotropic drug combination.
AN 2006:605351 HCAPLUS <<LOGINID::20091022>>
DN 145:55943
TI Methods of cardioprotection using dichloroacetate in combination with an inotrope
IN Lopaschuk, Gary D.; Collins-Nakai, Ruth
PA The Governors of the University of Alberta, Can.
SO PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006063446	A1	20060622	WO 2005-CA1894	20051215

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

US 20050282896 A1 20051222 US 2004-13666 20041215 <--

```
     US 20060194878       A1    20060831    US 2005-229101         20050916 <--
PRAI US 2004-13666        A     20041215
     US 2005-229101       A     20050916
     US 2002-268069       A1    20021007  <--
     US 2004-778791       A2    20040213
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
RE.CNT  9     THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10  ANSWER 5 OF 26  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Compositions treatment of chronic inflammatory diseases
AB   This invention defines novel compns. that can be used for clin. treatment
     of a class of chronic inflammatory diseases.  Increased generation of
     carbonyl substances, aldehydes and ketones, occurs at sites of chronic
     inflammation and is common to the etiologies of all of the clin. disorders
     addressed herein.  Such carbonyl substances are cytotoxic and addnl. serve
     to perpetuate and disseminate the inflammatory process.  This invention
     defines use of compns., the orally administered required primary agents of
     which are primary amine derivs. of benzoic acid capable of reacting with
     the carbonyl substances.  P-Aminobenzoic acid (or PABA) is an example of
     the required primary agent of the present invention.  PABA has a small
     mol. weight, is water soluble, has a primary amine group which reacts with
     carbonyl-containing substances and is tolerated by the body in relatively high
     dosages for extended periods.  The method of the present invention
     includes administration of a composition comprising: (1) an orally consumed
     primary agent; (2) a previously known medicament co-agent recognized as
     effective to treat a chronic inflammatory disease addressed herein
     administered to the mammalian subject via the oral route, other systemic
     routes of administration or via the topical route; and (3) optionally 1 or
     more addnl. orally consumed co-agent selected from the group consisting of
     antioxidants, vitamins, metabolites at risk of depletion, sulfhydryl
     co-agents, co-agents which may facilitate glutathione activity and
     nonabsorbable primary amine polymeric co-agents, so as to produce an
     additive or synergistic physiol. effect of an anti-inflammatory nature.
AN   2005:369133  HCAPLUS <<LOGINID::20091022>>
DN   142:435774
TI   Compositions treatment of chronic inflammatory diseases
IN   Shapiro, Howard K.
PA   USA
SO   U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 610,073,
     abandoned.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 5
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   US 20050090553       A1    20050428    US 2004-924945         20040824 <--
     US 20080234380       A1    20080925    US 2008-70518          20080220 <--
PRAI US 1992-906909       B2    19920630  <--
     US 1994-241603       B2    19940511  <--
     US 1997-814291       B2    19970310  <--
     US 2000-610073       B2    20000705  <--
     US 2004-924945       A2    20040824
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS   MARPAT 142:435774
OSC.G   1     THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L10  ANSWER 6 OF 26  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Pharmaceutical compositions
AB   The present invention relates to pharmaceutical compns. which are useful
```

in the treatment of diseases where excess mucus is present in the respiratory tract, such as cystic fibrosis and chronic obstructive pulmonary disease. In particular, the invention relates to pharmaceutical compns. for administration by pulmonary inhalation. Thus, in a first aspect of the present invention, a composition for assisting mucus clearance is provided, the composition comprising one or more mucoactive agents for reducing crosslinking within the mucus; for diluting the mucus; and/or for digesting naked DNA and cell debris within the mucus. Preferably, the composition according to the invention further has the effect of reducing inflammation. In one embodiment of the present invention, the composition comprises one or more mucoactive agents together with an addnl. active agent such as an anti-inflammatory agent. In a particularly preferred embodiment of the present invention, the mucoactive agent for reducing crosslinking is a glycosaminoglycan such as heparin. A further group of mucoactive agents capable of assisting mucus clearance are amino acids. Acetylcysteine (NAC) and the acetylcysteine salt derivative Nacystelyn (or NAL) are also effective mucoactive agents which are suitable for inclusion in the compns. of the present invention.

AN 2005:259852 HCAPLUS <<LOGINID::20091022>>

DN 142:329858

TI Pharmaceutical compositions

IN Morton, David; Ganderton, David; Staniforth, John; Kamlag, Yorick

PA Vectura Limited, UK

SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005025540	A2	20050324	WO 2004-GB3932	20040915 <--
	WO 2005025540	A3	20050616		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004271778	A1	20050324	AU 2004-271778	20040915 <--
	CA 2538399	A1	20050324	CA 2004-2538399	20040915 <--
	EP 1663151	A2	20060607	EP 2004-768478	20040915 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004014425	A	20061114	BR 2004-14425	20040915 <--
	CN 1874757	A	20061206	CN 2004-80032679	20040915 <--
	JP 2007505830	T	20070315	JP 2006-525902	20040915 <--
	SG 146649	A1	20081030	SG 2008-6902	20040915 <--
	NZ 545550	A	20090331	NZ 2004-545550	20040915 <--
	RU 2363448	C2	20090810	RU 2006-112583	20040915 <--
	KR 2006082865	A	20060719	KR 2006-705166	20060314 <--
	MX 2006002952	A	20060920	MX 2006-2952	20060315 <--
	NO 2006001254	A	20060411	NO 2006-1254	20060317 <--
	ZA 2006002748	A	20070530	ZA 2006-2748	20060404 <--
	IN 2006CN01269	A	20070629	IN 2006-CN1269	20060413 <--
	US 20070065373	A1	20070322	US 2006-571184	20060717 <--

PRAI GB 2003-21611 A 20030915 <--
GB 2003-27723 A 20031128 <--
WO 2004-GB3932 W 20040915
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Methods for preparing pharmaceutical compositions
AB The present invention relates to improvements in dry powder formulations comprising a pharmaceutically active agent for administration by inhalation, and in particular to methods of preparing dry powder compns. with improved properties. In particular, spray drying processes are adapted and adjusted to obtain active particles with higher fine particle fractions and fine particle doses. Spray drying 1% heparin from 10% methanol, ethanol and propan-1-ol resulted in a lowering of fine particle fraction from approx. 20% when spray dried from aqueous solvent using identical parameters to 2-6% fine particle fraction.
AN 2005:259847 HCAPLUS <<LOGINID::20091022>>
DN 142:303679
TI Methods for preparing pharmaceutical compositions
IN Morton, David; Kamlag, Yorick
PA Vectura Limited, UK
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005025535	A2	20050324	WO 2004-GB3938	20040915 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1663164	A2	20060607	EP 2004-768484	20040915 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	US 20060292081	A1	20061228	US 2006-570902	20060619 <--

PRAI GB 2003-21608 A 20030915 <--
GB 2004-9133 A 20040423
WO 2004-GB3938 W 20040915
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Treatment , prevention and management of pain, fever, neoplasm, inflammation, and hemorrhagic diseases by compound for any aspirin-related activity other than TAFI inhibition
AB The invention screens compds. for any aspirin-related activity other than TAFI inhibition, and also for non-inhibition of TAFI. Compds. identified

by the screening methods can be used to treat, prevent or manage in a patient pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder. Also provided is a method of evaluating test compds. for TAFI inhibitory activity wherein the TAFI inhibitory activity of these test compds. is compared to the TAFI inhibitory activity of aspirin or its derivs. or metabolites. Further provided is a method of treating, preventing or managing in a patient, a hemorrhagic or thrombotic disease or disorder with high dose aspirin or aspirin derivs. or metabolites. Also contemplated is a method of treating, preventing or managing in a patient, pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder comprising administering aspirin or a derivative thereof or any other therapeutic having at least one desired therapeutic or prophylactic activity of aspirin to a patient in need thereof and administering to the patient a factor that promotes TAFIa activity, e.g. stablized TAFIa, to ameliorate one or more adverse side effects of the therapeutic.

AN 2004:203632 HCAPLUS <<LOGINID::20091022>>

DN 140:247063

TI Treatment , prevention and management of pain, fever, neoplasm, inflammation, and hemorrhagic diseases by compound for any aspirin-related activity other than TAFI inhibition

IN Grennfield, Robert S.; An, Seong Soo A.; Trifonov, Latchezar; Vaugeois, Jean; Slemon, Claire

PA American Diagnostica, Inc., USA; Quebepharma Recherche, Inc.

SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004019882	A2	20040311	WO 2003-US27070	20030829 <--
	WO 2004019882	A3	20060413		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003265832	A1	20040319	AU 2003-265832	20030829 <--
	US 20050222096	A1	20051006	US 2003-651659	20030829 <--
	US 7119068	B2	20061010		
	EP 1664327	A2	20060607	EP 2003-791931	20030829 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 20080305508	A1	20081211	US 2006-544906	20061006 <--
PRAI	US 2002-407138P	P	20020829 <--		
	US 2002-407395P	P	20020830 <--		
	US 2003-651659	A3	20030829 <--		
	WO 2003-US27070	W	20030829 <--		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 140:247063

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Compositions and methods for the pulmonary delivery of aerosolized medicaments

AB According to the subject invention, dispersible dry powder pharmaceutical-based compns. are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (%w) water, usually below about 5%w and preferably less than about 3%w; a particle size of about 1.0-5.0 μm mass median diameter (MMD), usually 1.0-4.0 μm MMD, and preferably 1.0-3.0 μm MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 μm mass median aerodynamic diameter (MMAD), usually 1.5-4.5 μm MMAD, and preferably 1.5-4.0 μm MMAD. Such compns. are of pharmaceutical grade purity. Examples are provided of zinc insulin, parathyroid hormone, interleukin-1 receptor, calcitonin, α1-antitrypsin, β-interferon, heparin, lipid genetic vector, and adenoviral vector formulations for pulmonary delivery. Formulations of growth hormones suitable for treatment of short stature or renal failure are claimed.

AN 2004:11058 HCAPLUS <<LOGINID::20091022>>
DN 140:65165

TI Compositions and methods for the pulmonary delivery of aerosolized medicaments

IN Platz, Robert M.; Patton, John S.; Foster, Linda; Eljamal, Mohammed
PA Nektar Therapeutics, USA

SO U.S., 12 pp., Cont.-in-part of U.S. 6,231,851.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 20

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6673335	B1	20040106	US 2000-616236	20000714 <--
	EP 940154	A2	19990908	EP 1999-110369	19920702 <--
	EP 940154	B1	20070418		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
	EP 1693080	A2	20060823	EP 2006-9725	19920702 <--
	EP 1693080	A3	20070725		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC				
	AT 359842	T	20070515	AT 1999-110369	19920702 <--
	ES 2284226	T3	20071101	ES 1999-110369	19920702 <--
	US 5785049	A	19980728	US 1994-309691	19940921 <--
	NZ 329747	A	20000825	NZ 1995-329747	19950207 <--
	EP 1462096	A1	20040929	EP 2004-76082	19950207 <--
	EP 1462096	B1	20081210		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	EP 2036541	A1	20090318	EP 2008-21259	19950207 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	TW 576750	B	20040221	TW 1995-84101726	19950224 <--
	US 6582728	B1	20030624	US 1995-423515	19950414 <--
	WO 9531479	A1	19951123	WO 1995-US6008	19950515 <--
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6231851	B1	20010515	US 1997-737724	19970714 <--
	US 20020132787	A1	20020919	US 2001-978826	20011016 <--
	US 20020192164	A1	20021219	US 2002-141044	20020507 <--

```
     US 20030053959       A1    20030320    US 2002-141028         20020507 <--
     US 6737045           B2    20040518
     US 20030086877       A1    20030508    US 2002-245705         20020918 <--
     US 20040096400       A1    20040520    US 2003-612376         20030701 <--
     US 7521069           B2    20090421
     US 20040096401       A1    20040520    US 2003-613078         20030701 <--
     US 20050279349       A1    20051222    US 2003-693318         20031024 <--
     JP 2006077032        A     20060323    JP 2005-350682         20051205 <--
     US 20090203576       A1    20090813    US 2009-396525         20090303 <--
PRAI US 1992-910048       A2    19920708  <--
     US 1993-44358        B1    19930407  <--
     US 1994-246034       B2    19940518  <--
     US 1994-309691       A2    19940921  <--
     US 1994-313707       B2    19940927  <--
     US 1995-383475       B2    19950201  <--
     US 1995-417507       B2    19950404  <--
     US 1995-423515       A1    19950414  <--
     WO 1995-US6008       W     19950515  <--
     US 1997-737724       A2    19970714  <--
     US 1991-724915       A     19910702  <--
     EP 1992-914592       A3    19920702  <--
     EP 1999-110369       A3    19920702  <--
     US 1994-207472       A     19940307  <--
     US 1994-232849       A1    19940425  <--
     EP 1995-909506       A3    19950207  <--
     EP 2004-76082        A3    19950207  <--
     JP 1995-523456       A3    19950207  <--
     NZ 1995-281112       A1    19950207  <--
     US 1995-576885       A1    19951222  <--
     US 1996-668036       A1    19960617  <--
     US 1997-979024       A1    19971126  <--
     US 1999-427075       A3    19991026  <--
     US 1999-427836       A1    19991026  <--
     US 1999-447753       A1    19991122  <--
     US 2000-561690       A1    20000501  <--
     US 2000-616236       A1    20000714  <--
     US 2002-245706       A1    20020918  <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   2     THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT  19    THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10  ANSWER 10 OF 26  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Preparation of stable particles in frozen aqueous matrix for
     pharmaceutical suspensions
AB   The present invention discloses a composition of a stable suspension of a
     poorly water soluble pharmaceutical agent or cosmetic in the form of
     particles of the pharmaceutical or cosmetic suspended in a frozen aqueous
     matrix and method for its preparation  The composition is stable for a
prolonged
     period of time, preferably 6 mo or longer and is suitable for parenteral,
     oral, or non-oral routes such as pulmonary (inhalation
     ), ophthalmic, or topical administration.  Thus, suspension was obtained
     from Poloxamer-188 2.2, sodium deoxycholate 0.1, glycerin 2.2, and
     nabumetone 1%.
AN   2003:319276  HCAPLUS <<LOGINID::20091022>>
DN   138:343861
TI   Preparation of stable particles in frozen aqueous matrix for
     pharmaceutical suspensions
IN   Kipp, James E.; Doty, Mark J.; Rebbeck, Christine L.; Brynjelsen, Sean;
     Teresa, Konkel Jamie
```

PA Baxter International Inc., USA
SO U.S. Pat. Appl. Publ., 19 pp.
    CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20030077329	A1	20030424	US 2002-270267	20021011 <--
	US 7112340	B2	20060926		
	CA 2463313	A1	20030501	CA 2002-2463313	20021018 <--
	WO 2003035031	A1	20030501	WO 2002-US33270	20021018 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
	AU 2002337894	A1	20030506	AU 2002-337894	20021018 <--
	AU 2002337894	B2	20070712		
	EP 1435909	A1	20040714	EP 2002-773797	20021018 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005506999	T	20050310	JP 2003-537598	20021018 <--
	CN 1750811	A	20060322	CN 2002-820792	20021018 <--
	MX 2004003675	A	20040723	MX 2004-3675	20040419 <--
	US 20060222710	A1	20061005	US 2006-425122	20060619 <--
	US 20060222711	A1	20061005	US 2006-425125	20060619 <--
PRAI	US 2001-347548P	P	20011019	<--	
	US 2002-270267	A	20021011	<--	
	WO 2002-US33270	W	20021018	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 4   THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 306 THERE ARE 306 CITED REFERENCES AVAILABLE FOR THIS RECORD
             ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
AB Pharmaceutical compns. comprising a macromol. pharmaceutical agent in mixed micellar form are disclosed. The mixed micelles are formed from an alkali metal alkyl sulfate, and at least three different micelle-forming compds. Micelle size ranges between about 1 and 10 nm. Methods for making and using the compns. are also disclosed. A preferred method for administering the present composition is through the buccal region of the mouth. For example, to 1000 mg of powdered insulin dissolved in 10 mL of distilled water were added 50 mg sodium lauryl sulfate, 36 mg deoxycholate, 50 mg trihydroxyoxocholanylglycine (sodium glycocholate) and 20 mg dibasic Na phosphate followed by 250 mg glycerin, 40 mg m-cresol and 40 mg phenol. The solution (1 mL) was pipetted into 10 mL capacity glass vials, the vials were charged with HFA-134a propellant and stored at room temperature The oral insulin composition prepared (70 unit dose) performed much better in diabetic patients than hypoglycemic Metformin tablets in controlling glucose levels.
AN 2002:711276 HCAPLUS <<LOGINID::20091022>>
DN 137:237738
TI Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three

micelle-forming compounds
IN Modi, Pankaj
PA Generex Pharmaceuticals Incorporated, Can.
SO U.S., 11 pp., Cont.-in-part of U.S. Ser. No. 519,285.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 6451286	B1	20020917	US 2000-574504	20000519	<--
	US 6436367	B1	20020820	US 1999-251464	19990217	<--
	US 6312665	B1	20011106	US 1999-386284	19990831	<--
	US 6375975	B1	20020423	US 2000-519285	20000306	<--
	CA 2410065	A1	20011122	CA 2001-2410065	20010507	<--
	CA 2410065	C	20090407			
	WO 2001087268	A1	20011122	WO 2001-CA661	20010507	<--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	EP 1296648	A1	20030402	EP 2001-931281	20010507	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	NZ 522524	A	20030725	NZ 2001-522524	20010507	<--
	JP 2003533469	T	20031111	JP 2001-583737	20010507	<--
	US 20030035831	A1	20030220	US 2002-222699	20020816	<--
	US 6849263	B2	20050201			
	US 20030157029	A1	20030821	US 2002-222240	20020816	<--
	US 7087215	B2	20060808			
	MX 2002011436	A	20030606	MX 2002-11436	20021119	<--
	AU 2003259466	A1	20040303	AU 2003-259466	20030814	<--
	AU 2003259466	B2	20090108			
PRAI	US 1998-113239P	P	19981221	<--		
	US 1999-251464	A2	19990217	<--		
	US 1999-386284	A2	19990831	<--		
	US 2000-519285	A2	20000306	<--		
	US 2000-574504	A	20000519	<--		
	AU 2001-46746	A3	20010221	<--		
	WO 2001-IB515	W	20010221	<--		
	AU 2001-58112	A3	20010507	<--		
	WO 2001-CA661	W	20010507	<--		
	US 2002-222240	A	20020816	<--		
	WO 2003-IB3908	W	20030814	<--		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 12 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Method for treating respiratory disorders associated with pulmonary elastic fiber injury using polysaccharides
AB The present invention relates generally to the field of respiratory therapeutics, and in particular to the treatment of disorders of the lung matrix caused by damage to the elastic fibers of the lung matrix. More specifically, methods and materials are disclosed for the delivery to the

lungs of polysaccharides, derivs. thereof and/or drug conjugates, used in the treatment and/or prevention of pulmonary disorders. Chondroitin sulfate A, chondroitin sulfate C, heparan sulfate, hyaluronic acid HA 227K, HA 587K and HA 890K all demonstrated statistically significant protective effects on Mesogrow-L substrate when it was digested with porcine pancreatic elastase that was statistically significant. Of the substances tested, heparan sulfate seemed to have the greatest protective effect.

AN 2002:505406 HCAPLUS <<LOGINID::20091022>>

DN 137:57569

TI Method for treating respiratory disorders associated with pulmonary elastic fiber injury using polysaccharides

IN Cantor, Jerome O.; Kuo, Jing-Wen; Mihalko, Paul J.; Sachs, Dan; Turino, Gerard

PA USA

SO U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Ser. No. 79,209.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20020086852	A1	20020704	US 2001-863849	20010523 <--
	US 6391861	B1	20020521	US 1998-79209	19980514 <--
	EP 1772153	A2	20070411	EP 2007-241	20010214 <--
	EP 1772153	A3	20090513		
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
	US 20030171332	A1	20030911	US 2002-174221	20020617 <--
PRAI	US 1998-79209	A2	19980514	<--	
	US 2000-206612P	P	20000523	<--	
	EP 2001-923276	A3	20010214	<--	
	US 2001-863849	A2	20010523	<--	
	US 2001-298369P	P	20010615	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L10 ANSWER 13 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Pharmaceutical compositions for buccal and pulmonary application containing alkyl sulfates

AB Pharmaceutical compns. comprising a macromol. pharmaceutical agent in mixed micellar form are disclosed. The mixed micelles are formed from an alkali metal alkyl sulfate, and at least three different micelle-forming compds. as described in the specification. Micelle size ranges between about 1 and 10 nm. Methods for making and using the compns. are also disclosed. A preferred method for administering the present composition is through the buccal region of the mouth. A composition was prepared containing insulin which was treated with HCl, NaOH, and Na lauryl sulfate, deoxycholate, Na glycolate, dibasic Na phosphate, glycerol, m-cresol and phenol were added.

AN 2002:309784 HCAPLUS <<LOGINID::20091022>>

DN 136:330558

TI Pharmaceutical compositions for buccal and pulmonary application containing alkyl sulfates

IN Modi, Pankaj

PA Generex Pharmaceuticals Incorporated, Can.

SO U.S., 11 pp., Cont.-in-part of U.S. Ser. No. 386,284.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 6375975	B1	20020423	US 2000-519285	20000306	<--
	US 6436367	B1	20020820	US 1999-251464	19990217	<--
	US 6312665	B1	20011106	US 1999-386284	19990831	<--
	US 6451286	B1	20020917	US 2000-574504	20000519	<--
	CA 2401942	A1	20010913	CA 2001-2401942	20010221	<--
	WO 2001066085	A2	20010913	WO 2001-IB515	20010221	<--
	WO 2001066085	A3	20020411			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	EP 1261320	A2	20021204	EP 2001-919686	20010221	<--
	EP 1261320	B1	20080625			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	JP 2003525891	T	20030902	JP 2001-564738	20010221	<--
	AU 783431	B2	20051027	AU 2001-46746	20010221	<--
	AT 398998	T	20080715	AT 2001-919686	20010221	<--
	ES 2309059	T3	20081216	ES 2001-919686	20010221	<--
	US 20030035831	A1	20030220	US 2002-222699	20020816	<--
	US 6849263	B2	20050201			
	US 20030157029	A1	20030821	US 2002-222240	20020816	<--
	US 7087215	B2	20060808			
	MX 2002008749	A	20030414	MX 2002-8749	20020906	<--
	AU 2003259466	A1	20040303	AU 2003-259466	20030814	<--
	AU 2003259466	B2	20090108			
PRAI	US 1998-113239P	P	19981221	<--		
	US 1999-251464	A2	19990217	<--		
	US 1999-386284	A2	19990831	<--		
	US 2000-519285	A2	20000306	<--		
	US 2000-574504	A2	20000519	<--		
	AU 2001-46746	A3	20010221	<--		
	WO 2001-IB515	W	20010221	<--		
	AU 2001-58112	A3	20010507	<--		
	WO 2001-CA661	W	20010507	<--		
	US 2002-222240	A	20020816	<--		
	WO 2003-IB3908	W	20030814	<--		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 14 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Treating respiratory disorders associated with pulmonary elastic fiber injury with polysaccharides
AB The present invention relates generally to the field of respiratory therapeutics, and in particular to the treatment of disorders of the lung matrix caused by damage to the elastic fibers of the lung matrix. More specifically, methods and materials are disclosed for the delivery to the lungs of polysaccharides, derivs. thereof and/or drug conjugates, used in the treatment and/or prevention of pulmonary disorders.
Examples are given for the effect of hyaluronic acid on pulmonary emphysema induced by pancreatic elastase, and neutrophil elastase.
AN 2001:903815 HCAPLUS <<LOGINID::20091022>>

DN 136:42842
TI Treating respiratory disorders associated with pulmonary elastic fiber injury with polysaccharides
IN Cantor, Jerome; Kuo, Jing Wen; Milhalko, Paul J.; Sachs, Dan; Torino, Gerard
PA The Trustees of Columbia University In the City of New York, USA; Exhale Therapeutics, Inc.
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001093846	A2	20011213	WO 2001-US16589	20010523 <--
	WO 2001093846	A3	20020523		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2438656	A1	20020822	CA 2001-2438656	20010214 <--
	WO 2002064149	A1	20020822	WO 2001-US40105	20010214 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001249985	A1	20020828	AU 2001-249985	20010214 <--
	EP 1379256	A1	20040114	EP 2001-923276	20010214 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EP 1772153	A2	20070411	EP 2007-241	20010214 <--
	EP 1772153	A3	20090513		
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
	CA 2410577	A1	20011213	CA 2001-2410577	20010523 <--
	EP 1292314	A2	20030319	EP 2001-939283	20010523 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004513071	T	20040430	JP 2002-501419	20010523 <--
PRAI	US 2000-206612P	P	20000523 <--		
	WO 2001-US40105	W	20010214 <--		
	EP 2001-923276	A3	20010214 <--		
	WO 2001-US16589	W	20010523 <--		

OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 15 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Micellar pharmaceutical compositions for buccal and pulmonary application
AB Pharmaceutical compns. comprising a macromol. pharmaceutical agent in

mixed micellar form are disclosed. The mixed micelles are formed from an alkali metal alkyl sulfate, and at least three different micelle-forming compds. as described in the specification. Micelle size ranges between about 1 and 10 nm. A composition contained powdered insulin, Na lauryl sulfate,
deoxycholate, Na glycocholate, dibasic Na phosphate, and glycerin. A preferred method for administering the present composition is through the buccal region of the mouth.

AN 2001:850912 HCAPLUS <<LOGINID::20091022>>
DN 136:11112
TI Micellar pharmaceutical compositions for buccal and pulmonary application
IN Modi, Pankaj
PA Generex Pharmaceuticals Inc., Can.
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001087268	A1	20011122	WO 2001-CA661	20010507 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6451286	B1	20020917	US 2000-574504	20000519 <--
	CA 2410065	A1	20011122	CA 2001-2410065	20010507 <--
	CA 2410065	C	20090407		
	EP 1296648	A1	20030402	EP 2001-931281	20010507 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 522524	A	20030725	NZ 2001-522524	20010507 <--
	JP 2003533469	T	20031111	JP 2001-583737	20010507 <--
	MX 2002011436	A	20030606	MX 2002-11436	20021119 <--
	AU 2003259466	A1	20040303	AU 2003-259466	20030814 <--
	AU 2003259466	B2	20090108		
	AU 2006200276	A1	20060209	AU 2006-200276	20060123 <--
	AU 2006200276	B2	20071129		
PRAI	US 2000-574504	A	20000519	<--	
	US 1998-113239P	P	19981221	<--	
	US 1999-251464	A2	19990217	<--	
	US 1999-386284	A2	19990831	<--	
	US 2000-519285	A2	20000306	<--	
	AU 2001-46746	A3	20010221	<--	
	WO 2001-IB515	W	20010221	<--	
	AU 2001-58112	A3	20010507	<--	
	WO 2001-CA661	W	20010507	<--	
	US 2002-222240	A	20020816	<--	
	WO 2003-IB3908	W	20030814	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 16 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Pressurized container having an aerosolized pharmaceutical composition

AB A pressurized container with an aerosol pharmaceutical formulation, and a process for making the formulation, are provided. The formulation comprises a pharmaceutical agent, a phenol, glycerin or polyglycerin, and an addnl. ingredient such as an alkali metal alkyl sulfate, polidocanol alkyl ether or the like. The formulation is placed in the pressurized container, which is then charged with a propellant. A method of treating a medical condition, by spraying the formulation into the mouth or lungs, is also provided. For example, powdered insulin was dissolved in water using 5M HCl (pH 2) solution dropwise until the insulin was solubilized completely. The solution was then neutralized and 7 mg sodium lauryl sulfate, 7 mg polyoxyethylene ether (10-lauryl) and 7 mg trihydroxy oxo cholanyl glycine were added and dissolved completely. Lecithin, solubilized in a water alc. solution (7 mg/mL) was then added while stirring. The resulting mixed micellar solution had about 200 units insulin. To this mixture 5 mg phenol, 5 mg m-cresol and 10 mg glycerin were added. The solution was pipetted (1 mL/vial) into 10 mL capacity glass vials. The vials were then charged with HFA 134a propellant and the amount of propellant was adjusted to 9 mL shot size in order to deliver 2 units insulin per actuation of the aerosol vial. The aqueous pharmaceutical composition and the propellant remained as sep. phases. Prior to discharging shots of the formulation, shaking of the vial was necessary in order to entrain the pharmaceutical in the propellant phase. The particle size was determined to be about 7 μm, suggesting that there would be no deep lung deposition formulation and that most of the formulation would be deposited in the buccal cavity.

AN 2001:828918 HCAPLUS <<LOGINID::20091022>>
DN 135:362585

TI Pressurized container having an aerosolized pharmaceutical composition

IN Modi, Pankaj
PA Generex Pharmaceuticals, Inc., Can.

SO U.S., 10 pp., Cont.-in-part of U.S. Ser. No. 272,563.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6315984	B1	20011113	US 1999-388344	19990903 <--
	US 6350432	B1	20020226	US 1999-272563	19990319 <--
	CA 2364610	A1	20000928	CA 2000-2364610	20000310 <--
	CA 2364610	C	20061219		
	WO 2000056291	A1	20000928	WO 2000-CA260	20000310 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1162958	A1	20011219	EP 2000-908880	20000310 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002539240	T	20021119	JP 2000-606197	20000310 <--
	NZ 514319	A	20021126	NZ 2000-514319	20000310 <--
	AU 766745	B2	20031023	AU 2000-31400	20000310 <--
	MX 2001009466	A	20020514	MX 2001-9466	20010919 <--
PRAI	US 1999-272563	A2	19990319 <--		
	US 1999-388344	A	19990903 <--		
	WO 2000-CA260	W	20000310 <--		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 17 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Aerosol formulations for buccal and pulmonary application
AB A mixed micellar aerosol pharmaceutical formulation is provided. The formulation comprises a pharmaceutical agent, an alkali metal alkyl sulfate, at least three micelle-forming compds., a phenol and a propellant. The propellant provides enhanced absorption of the pharmaceutical agent in the buccal region. A process of making and a method of administering the composition are also included. The aerosol formulations of invention resulted in comparable blood glucose level with injection formulations in diabetic volunteers.
AN 2001:808253 HCAPLUS <<LOGINID::20091022>>
DN 135:348902
TI Aerosol formulations for buccal and pulmonary application
IN Modi, Pankaj
PA Generex Pharmaceuticals Incorporated, Can.
SO U.S., 11 pp., Cont.-in-part of U.S. Ser. No. 251,464.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6312665	B1	20011106	US 1999-386284	19990831 <--
	US 6436367	B1	20020820	US 1999-251464	19990217 <--
	CA 2354148	A1	20000629	CA 1999-2354148	19991216 <--
	WO 2000037051	A1	20000629	WO 1999-CA1231	19991216 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1140019	A1	20011010	EP 1999-962009	19991216 <--
	EP 1140019	B1	20030625		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002532536	T	20021002	JP 2000-589162	19991216 <--
	JP 3818851	B2	20060906		
	NZ 512188	A	20021025	NZ 1999-512188	19991216 <--
	AU 760445	B2	20030515	AU 2000-18518	19991216 <--
	AT 243498	T	20030715	AT 1999-962009	19991216 <--
	EP 1338272	A1	20030827	EP 2003-2417	19991216 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	ES 2203227	T3	20040401	ES 1999-962009	19991216 <--
	US 6375975	B1	20020423	US 2000-519285	20000306 <--
	US 6451286	B1	20020917	US 2000-574504	20000519 <--
	MX 2001006380	A	20020424	MX 2001-6380	20010621 <--
	US 20030035831	A1	20030220	US 2002-222699	20020816 <--
	US 6849263	B2	20050201		
	US 20030157029	A1	20030821	US 2002-222240	20020816 <--
	US 7087215	B2	20060808		
PRAI	US 1998-113239P	P	19981221 <--		
	US 1999-251464	A2	19990217 <--		

```
     US 1999-386284       A     19990831  <--
     EP 1999-962009       A3    19991216  <--
     WO 1999-CA1231       W     19991216  <--
     US 2000-519285       A2    20000306  <--
     US 2000-574504       A2    20000519  <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   4     THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT  10    THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10  ANSWER 18 OF 26  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Pharmaceutical compositions for buccal and pulmonary application
AB   Pharmaceutical compns. comprising a macromol. pharmaceutical agent in
     mixed micellar form are disclosed.  The mixed micelles are formed from an
     alkali metal alkyl sulfate, and at least 3 different micelle-forming
     compds.  Micelle size ranges between about 1 and 10 nm.  A preferred
     method for administering the present composition is through the buccal region
     of the mouth.  A solution of powdered insulin (100 mg) in 10 mL water was
prepared
     and mixed with sodium lauryl sulfate 50, deoxycholate 36,
     trihydroxyoxocholanylglycine 50, and dibasic sodium phosphate 20 mg.  This
     mixture was then mixed with 250 mg glycerin, 40 mg m-cresol, and 40 mg
     phenol.
AN   2001:676576  HCAPLUS <<LOGINID::20091022>>
DN   135:231706
TI   Pharmaceutical compositions for buccal and pulmonary application
IN   Modi, Pankaj
PA   Generex Pharmaceuticals Inc., Can.
SO   PCT Int. Appl., 28 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 8
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2001066085         A2    20010913    WO 2001-IB515           20010221 <--
     WO 2001066085         A3    20020411
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
             ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 6375975            B1    20020423    US 2000-519285          20000306 <--
     CA 2401942            A1    20010913    CA 2001-2401942         20010221 <--
     EP 1261320            A2    20021204    EP 2001-919686          20010221 <--
     EP 1261320            B1    20080625
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2003525891         T     20030902    JP 2001-564738          20010221 <--
     AU 783431             B2    20051027    AU 2001-46746           20010221 <--
     MX 2002008749         A     20030414    MX 2002-8749            20020906 <--
     AU 2003259466         A1    20040303    AU 2003-259466          20030814 <--
     AU 2003259466         B2    20090108
PRAI US 2000-519285        A     20000306  <--
     US 1998-113239P       P     19981221  <--
     US 1999-251464        A2    19990217  <--
     US 1999-386284        A2    19990831  <--
```

```
     US 2000-574504       A     20000519  <--
     AU 2001-46746        A3    20010221  <--
     WO 2001-IB515        W     20010221  <--
     AU 2001-58112        A3    20010507  <--
     WO 2001-CA661        W     20010507  <--
     US 2002-222240       A     20020816  <--
     WO 2003-IB3908       W     20030814  <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   2     THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT  10    THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10  ANSWER 19 OF 26  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Nucleic acid delivery system
AB   The present invention is directed to a composition and pharmaceutical prepns.
     for introducing nucleic acids including oligo- or poly-nucleotides into
     cells in a host tissue by a delivery system and a method of preparing such a
     composition  The composition for delivery of nucleic acids comprises polymeric
     carrier particles that are essentially free of groups having a pos. elec.
     charge and the nucleic acids are provided essentially on the surface of
     the particles.  The carrier particle is insol. in water but suitably it is
     able to absorb water quickly.
AN   2001:434905  HCAPLUS <<LOGINID::20091022>>
DN   135:37173
TI   Nucleic acid delivery system
IN   Guan, Holly
PA   Artursson, Per, Swed.
SO   PCT Int. Appl., 45 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2001041810         A2    20010614    WO 2000-EP12339         20001207 <--
     WO 2001041810         A3    20020425
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG,
             CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2393526            A1    20010614    CA 2000-2393526         20001207 <--
     EP 1235597            A2    20020904    EP 2000-981347          20001207 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2003516365         T     20030513    JP 2001-543154          20001207 <--
     AU 782370             B2    20050721    AU 2001-18621           20001207 <--
     MX 2002005697         A     20040910    MX 2002-5697            20020607 <--
     US 20030166594        A1    20030904    US 2003-149458          20030218 <--
PRAI SE 1999-4475          A     19991208  <--
     US 1999-171307P       P     19991221  <--
     WO 2000-EP12339       W     20001207  <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
RE.CNT  1     THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

L10 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Pharmaceutical solubilized in aerosol propellant
AB A formulation with a pharmaceutical agent solubilized in a propellant can be administered buccally or into the lungs using a metered dose spray applicator. The pharmaceutical agent is dispensed from a pressurized container containing a stable solubilized mixture of propellant which is liquid under pressure and an intermediate formulation. The intermediate formulation comprises the proteinic pharmaceutical agent, water, first ingredient, second ingredient and at least one third ingredient. The first ingredient is glycerin and/or polyglycerin in an amount of 1-50 % of the intermediate formulation. The second ingredient is phenol and/or Me phenol in an amount of 1-20 % of the intermediate formulation. Each third ingredient is selected from the group consisting of alkali metal C8 to C22 alkyl sulfate, polidocanol C6 to C40 alkyl ethers, trihydroxy sodium oxo-cholanyl glycines, polyoxyethylene sorbitan ethers, alkyl-aryl polyether alcs., hyaluronic acid and pharmaceutically suitable salts thereof, monoolein, triolein, lysine, polylysine, oleic acid, linoleic acid, linolenic acid, monooleates and laurates, glycolic acid, lactic acid, chenodeoxycholate, deoxycholate, chamomile extract, cucumber extract, borage oil and evening primrose oil and mixts. thereof, in an amount of 1-50 % of the intermediate formulation. The total concentration of first, second and third ingredients is less than 90 % of the intermediate formulation.
AN 2000:688050 HCAPLUS <<LOGINID::20091022>>
DN 133:256836
TI Pharmaceutical solubilized in aerosol propellant
IN Modi, Pankaj
PA Generex Pharmaceuticals Inc., Can.
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056291	A1	20000928	WO 2000-CA260	20000310 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6350432	B1	20020226	US 1999-272563	19990319 <--
	US 6315984	B1	20011113	US 1999-388344	19990903 <--
	CA 2364610	A1	20000928	CA 2000-2364610	20000310 <--
	CA 2364610	C	20061219		
	EP 1162958	A1	20011219	EP 2000-908880	20000310 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002539240	T	20021119	JP 2000-606197	20000310 <--
	NZ 514319	A	20021126	NZ 2000-514319	20000310 <--
	AU 766745	B2	20031023	AU 2000-31400	20000310 <--
	MX 2001009466	A	20020514	MX 2001-9466	20010919 <--
PRAI	US 1999-272563	A	19990319 <--		
	US 1999-388344	A	19990903 <--		
	WO 2000-CA260	W	20000310 <--		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Pulmonary drug delivery
AB An aerosol pharmaceutical formulation comprises a protein pharmaceutical agent, water, a phenol and a propellant. The phenol is phenol and/or Me phenol in a concentration of from 1 to 10 weight/weight% of the total formulation. The propellant is a C1-C2 dialkyl ether, butanes, fluorocarbon propellant, hydrogen-containing fluorocarbon propellant, chlorofluorocarbon propellant, or hydrogen-containing chlorofluorocarbon propellant, or mixts. thereof. Optionally, excipients selected from salts, antioxidants, coloring agents, flavoring agents, protease inhibitors, stabilizers, glycerin, polyglycerin, lysine, polylysine and mixts. thereof, may be present. Preferably, the formulation is administered buccally, using a metered dose dispenser. An example is given for insulin as the active agent.
AN 2000:441603 HCAPLUS <<LOGINID::20091022>>
DN 133:63986
TI Pulmonary drug delivery
IN Modi, Pankaj
PA Generex Pharmaceuticals Inc., Can.
SO PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000037052	A1	20000629	WO 1999-CA1232	19991216 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6294153	B1	20010925	US 1999-397102	19990916 <--
	CA 2353847	A1	20000629	CA 1999-2353847	19991216 <--
	CA 2353847	C	20070306		
	EP 1143931	A1	20011017	EP 1999-962010	19991216 <--
	EP 1143931	B1	20061004		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	JP 2002532537	T	20021002	JP 2000-589163	19991216 <--
	JP 3818852	B2	20060906		
	NZ 512272	A	20021220	NZ 1999-512272	19991216 <--
	AU 759051	B2	20030403	AU 2000-18519	19991216 <--
	AT 341309	T	20061015	AT 1999-962010	19991216 <--
	ES 2274651	T3	20070516	ES 1999-962010	19991216 <--
	MX 2001006377	A	20020506	MX 2001-6377	20010621 <--
PRAI	US 1998-113243P	P	19981221 <--		
	US 1999-397102	A	19990916 <--		
	WO 1999-CA1232	W	19991216 <--		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 22 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Aerosol formulations for buccal and pulmonary application

AB A mixed micellar aerosol pharmaceutical formulation includes a micellar protein pharmaceutical agent, an alkali metal lauryl sulfate, at least three micelle forming compds., a phenol and a propellant. The micelle forming compds. are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxocholanyl glycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogs thereof, polydocanol alkyl ethers and analogs thereof, chenodeoxycholate and deoxycholate. The amount of each micelle forming compound is present in a concentration of from 1 to 20 weight/weight% of the total formulation, and the total concentration of micelle forming compds. are less than 50 weight/weight% of the formulation. The propellant, e.g., a fluorocarbon propellant, provides enhanced absorption of the pharmaceutical agent, particularly in the buccal cavity. An example was given using insulin as the active ingredient.

AN 2000:441602 HCAPLUS <<LOGINID::20091022>>

DN 133:63985

TI Aerosol formulations for buccal and pulmonary application

IN Modi, Pankaj

PA Generex Pharmaceuticals Inc., Can.

SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000037051	A1	20000629	WO 1999-CA1231	19991216 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6436367	B1	20020820	US 1999-251464	19990217 <--
	US 6312665	B1	20011106	US 1999-386284	19990831 <--
	CA 2354148	A1	20000629	CA 1999-2354148	19991216 <--
	EP 1140019	A1	20011010	EP 1999-962009	19991216 <--
	EP 1140019	B1	20030625		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002532536	T	20021002	JP 2000-589162	19991216 <--
	JP 3818851	B2	20060906		
	NZ 512188	A	20021025	NZ 1999-512188	19991216 <--
	AU 760445	B2	20030515	AU 2000-18518	19991216 <--
	AT 243498	T	20030715	AT 1999-962009	19991216 <--
	MX 2001006380	A	20020424	MX 2001-6380	20010621 <--
PRAI	US 1998-113239P	P	19981221 <--		
	US 1999-251464	A	19990217 <--		
	US 1999-386284	A	19990831 <--		
	WO 1999-CA1231	W	19991216 <--		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 23 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Superparamagnetic iron oxide contrast agent
AB Particulate contrast agents, especially contrast agents for magnetic resonance imaging, have a metal oxide, preferably superparamagnetic Fe oxide, core provided with a low coating d. of a polyelectrolyte coating agent selected from structural polysaccharides and synthetic polymers, especially polyamino acids. Unlike conventional coated particulates, these particles have reduced or no effect on cardiovascular parameters, platelet depletion, complement activation, and blood coagulation. Thus, when a dilute suspension containing 0.5 g synthetic magnetite particles was mixed with 10,000 IU heparin, 54% of the heparin was adsorbed to the particle surface; the ζ potential was -61 mV. These coated particles were unaffected by autoclaving and, when injected i.v., caused only minor and transient changes in mean systemic and pulmonary arterial pressures and circulating platelet counts in rabbits and in partial thromboplastin time in rats.
AN 1996:388321 HCAPLUS <<LOGINID::20091022>>
DN 125:41798
OREF 125:7937a,7940a
TI Superparamagnetic iron oxide contrast agent
IN Fahlvik, Anne Kjersti; Naevestad, Anne; Gundersen, Helge; Strande, Per; Klaveness, Jo; Jacobsen, Anne
PA Nycomed Imaging A/s, Norway; Cockbain, Julian Roderick Michaelson
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9609840	A1	19960404	WO 1994-GB2097	19940927 <--
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2201158	A1	19960404	CA 1994-2201158	19940927 <--
	AU 9477029	A	19960419	AU 1994-77029	19940927 <--
	AU 687093	B2	19980219		
	EP 783325	A1	19970716	EP 1994-927724	19940927 <--
	EP 783325	B1	19991201		
	EP 783325	B2	20040331		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1174510	A	19980225	CN 1994-195204	19940927 <--
	CN 1071580	C	20010926		
	JP 10506121	T	19980616	JP 1994-511474	19940927 <--
	AT 187079	T	19991215	AT 1994-927724	19940927 <--
	ES 2139097	T3	20000201	ES 1994-927724	19940927 <--
	RU 2147243	C1	20000410	RU 1997-106773	19940927 <--
	NO 9701436	A	19970523	NO 1997-1436	19970325 <--
PRAI	EP 1994-927724	A	19940927 <--		
	WO 1994-GB2097		19940927 <--		

OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 24 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Superoxide dismutase, mimetics thereof, therapeutic use thereof, and isolation and sequencing of human EC superoxide dismutase gene

AB The present invention relates, in general, to a method of modulating physiol. and pathol. processes and, in particular, to a method of modulating intra- and extracellular levels of superoxide radicals and thereby processes in which such radicals are a participant. The invention also relates to compds. and compns. suitable for use in such methods. The invention claims superoxide dismutase (SOD) mimetics which comprise a N-containing macrocyclic moiety and a cell surface or extracellular matrix targeting moiety, or a pharmaceutically acceptable salt thereof. The macrocyclic moiety of the SOD mimetic is e.g. a porphyrin derivative (Markush included) which may be complexed with manganese, copper, or iron; the targeting moiety is e.g. a peptide sequence (sequences included). Also included is the isolation and sequencing of the human gene for EC-SOD (tetrameric glycosylated copper- and zinc-containing SOD found in the extracellular fluid and bound to the extracellular matrix). A SOD mimetic protected against paraquat-induced injury in cultured rat pulmonary epithelial cells.

AN 1995:721195 HCAPLUS <<LOGINID::20091022>>
DN 123:218443
OREF 123:38599a,38602a

TI Superoxide dismutase, mimetics thereof, therapeutic use thereof, and isolation and sequencing of human EC superoxide dismutase gene

IN Crapo, James D.; Fridovich, Irwin; Oury, Tim; Day, Brian J.; Folz, Rodney J.; Freeman, Bruce A.
PA Duke University, USA; University of Alabama at Birmingham Research Foundation

SO PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9510185	A1	19950420	WO 1994-US11558	19941013 <--
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2174236	A1	19950420	CA 1994-2174236	19941013 <--
	CA 2174236	C	20080212		
	CA 2614621	A1	19950420	CA 1994-2614621	19941013 <--
	AU 9479763	A	19950504	AU 1994-79763	19941013 <--
	AU 702596	B2	19990225		
	EP 723398	A1	19960731	EP 1994-930729	19941013 <--
	EP 723398	B1	20050323		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 09505805	T	19970610	JP 1995-512010	19941013 <--
	EP 1442747	A1	20040804	EP 2004-10434	19941013 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	AT 291351	T	20050415	AT 1994-930729	19941013 <--
	ES 2237753	T3	20050801	ES 1994-930729	19941013 <--
	AU 769217	B2	20040122	AU 2000-53511	20000821 <--
	AU 2004201624	A1	20040513	AU 2004-201624	20040420 <--
PRAI	US 1993-136207	A	19931015 <--		
	CA 1994-2174236	A3	19941013 <--		
	EP 1994-930729	A3	19941013 <--		
	WO 1994-US11558	W	19941013 <--		
	AU 1996-63870	A3	19960607 <--		
	AU 2000-53511	A	20000821 <--		

OS MARPAT 123:218443

L10 ANSWER 25 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Method and apparatus for administering dehydrated drug-containing liposomes by inhalation
AB Self-contained apparatus or systems and methods for delivering a selected amount of drug, efficiently and reproducibly, in liposome-encapsulated form are described. The apparatus includes liposome particles formed by spray drying a dilute aqueous suspension of the liposomes. The particles formed have a fine particle size, retain the majority of their originally encapsulated material, and are stable in a preferred formulation, when suspended in a fluorocarbon solvent. The liposomes are preferably formed from partially or totally saturated phospholipids and dried in a stream of heated gas whose temperature does not degrade the lipids or structural integrity of the liposomes. The apparatus further includes a self-contained delivery device for producing an airborne suspension of the liposomes containing a metered dose of drug, e.g. a metered-dose spray device. Alternatively, the liposomes and a metered amount of the liposome-entrapped drug are contained in individual packets and the delivery device is e.g. a propellant spray device designed to release a stream of aerosolized propellant particles through the packet to entrain the liposomes in the stream. Views of various embodiments of liposome delivery apparatus are shown. Liposomes containing encapsulated metaproterenol sulfate (MPS) were prepared by solvent injection, diluted, and spray dried. The spray-dried liposomes were suspended in Freon 115 or Freon 114, stored for several days, and sprayed onto a moist plate for rehydration. The amount of encapsulated drug on rehydration was .apprx.50%. This delivery system has the advantages of (a) reduced side effects due to rapid systemic drug uptake; (b) improved therapeutic action over an extended period; and (c) the ability to modulate rate of drug release from the target site.
AN 1990:503430 HCAPLUS <<LOGINID::20091022>>
DN 113:103430
OREF 113:17379a
TI Method and apparatus for administering dehydrated drug-containing liposomes by inhalation
IN Radhakrishnan, Ramachandran; Mihalko, Paul J.; Abra, Robert M.
PA Liposome Technology, Inc., USA
SO U.S., 11 pp. Cont.-in-part of U.S. Ser. No. 737,221, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4895719	A	19900123	US 1987-22937	19870306 <--
	US 5340587	A	19940823	US 1989-366299	19890613 <--
	US 5192528	A	19930309	US 1989-444360	19891201 <--
PRAI	US 1985-737221	B2	19850522 <--		
	US 1986-860528	B2	19860507 <--		
	US 1986-937609	A2	19861203 <--		
	US 1986-937607	A	19861203 <--		
	US 1987-22937	A2	19870306 <--		
	US 1987-22669	B1	19870319 <--		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 59 THERE ARE 59 CAPLUS RECORDS THAT CITE THIS RECORD (59 CITINGS)
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 26 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN
TI New carbohydrate site in mutant antithrombin (7 Ile → Asn) with decreased heparin affinity
AB A mutant antithrombin was isolated from the plasma of a patient with

pulmonary embolism. The new protein, which accounted for 55% of the antithrombin, had decreased heparin affinity and contained 2 components when analyzed on the basis of either charge or mol. mass. Sialidase and endo-β-N-acetylglucosaminidase F treatment suggested that this heterogeneity was due to a partial glycosylation occurring at a new carbohydrate attachment sequence. Peptide mapping by reverse-phase HPLC showed that the abnormality involved the N-terminal tryptic peptide. Sequence anal. demonstrated that the underlying mutation was 7 Ile → Asn which introduces a new Asn-Cys-Thr glycosylation sequence. This new oligosaccharide attachment site occupies the base of the proposed heparin-binding site, and the finding explains the consequent decrease in heparin affinity.

AN 1988:609085 HCAPLUS <<LOGINID::20091022>>
DN 109:209085
OREF 109:34555a,34558a
TI New carbohydrate site in mutant antithrombin (7 Ile → Asn) with decreased heparin affinity
AU Brennan, Stephen O.; Borg, Jeanne Yvonne; George, Peter M.; Soria, Claudine; Soria, Jeannette; Caen, Jacques; Carrell, Robin W.
CS Christchurch Sch. Med., Christchurch Hosp., Christchurch, N. Z.
SO FEBS Letters (1988), 237(1-2), 118-22
CODEN: FEBLAL; ISSN: 0014-5793
DT Journal
LA English